CBD-CONTAINING BEVERAGE

Abstract

The invention relates to a CBD-containing liquid formulation, and in particular to a beverage comprising at least one emulsifier.

Claims

1-11. (canceled)

12. A liquid formulation, comprising: cannabidiol (CBD), at least one emulsifier, and water, wherein the emulsifier comprises a non-ionic emulsifier and the CBD is in a range of up to 500 mg/L of the liquid formulation.

13. The liquid formulation according to claim 12, wherein the non-ionic emulsifier is a partial fatty acid ester, a fatty alcohol, a sterol, a polyethylene glycol, an ethoxylated fatty acid, an ethoxylated fatty alcohol, an ethoxylated sorbitan ester, a sugar, or a polyglycerol.

14. The liquid formulation according to claim 12, wherein the ethoxylated sorbitan ester is Tween 20, Tween, 60, or Tween 80.

15. The liquid formulation according to claim 12, wherein the emulsifier further comprises an anionic emulsifier, a cationic emulsifier, an amphoteric emulsifier or a natural emulsifier, or a mixture thereof

16. The liquid formulation according to claim 15, wherein the anionic emulsifier is sodium stearate, a fatty alcohol sulfate, a mono, di- and tri-alkyl phosphoric acid ester or an ethoxylate thereof, a fatty acid lactate ester, a fatty acid citrate ester, or a fatty acid citro-glycerin ester.

17. The liquid formulation according to claim 15, wherein the cationic emulsifier is a quaternary ammonium compound having a long-chain aliphatic group.

18. The liquid formulation according to claim 15, wherein the amphoteric emulsifier is an alkylamininoalkane carboxylic acid, a betaine, a sulfobetaine, or an imidazoline derivative.

19. The liquid formulation according to claim 15, wherein the natural emulsifier is beeswax, a lecithin or a sterol.

20. The liquid formulation according to claim 12, wherein the emulsifier further comprises a rubber, gum arabic, a pectin, a starch, Purity Gum, or a caseinate from milk, or a mixture thereof.

21. The liquid formulation according to claim 12, wherein the CBD is in the range of up to 300 mg/L of the liquid formulation.

22. The liquid formulation according to claim 12, wherein the CBD is in the range of up to 100 mg/L of the liquid formulation.

23. The liquid formulation according to claim 12, wherein the CBD is in the range of 50 mg/L to 300 mg/L of the liquid formulation.

24. The liquid formulation according to claim 12, wherein the CBD is in the range of 50 mg/L to 100 mg/L of the liquid formulation.

25. A beverage or base material comprising the liquid formulation as claimed in claim 12.

26. The beverage or base material according to claim 25, wherein the beverage or base material is an energy drink, mineral water, lemonade, tonic water, fruit, fruit juice, milk, whey, soft drink, alcoholic beverage or as a drinking water preparation.

27. A liquid formulation, comprising: cannabidiol (CBD), at least one emulsifier comprising a non-ionic emulsifier and a lecithin, and water, wherein the non-ionic emulsifier is an ethoxylated sorbitan ester and the CBD is in a range of up to 500 mg/L of the liquid formulation.

28. The liquid formulation according to claim 27, wherein the ethoxylated sorbitan ester is Tween 20, Tween, 60, or Tween 80.

29. The liquid formulation according to claim 27, wherein the CBD is in the range of 50 mg/L to 300 mg/L of the liquid formulation.

30. A beverage or base material comprising the liquid formulation as claimed in claim 27.

31. The beverage or base material according to claim 30, wherein the beverage or base material is an energy drink, mineral water, lemonade, tonic water, fruit, fruit juice, milk, whey, soft drink, alcoholic beverage or as a drinking water preparation.

Description

[0020] FIGS. 1 to 3 show electropharmacograms from electroencephalography (EEG) of adult rats (>3 months old), wherein a dosage of 1 mg/kg (body weight) (FIG. 1), 5 mg/kg (body weight (FIGS. 2), and 15 mg/kg (body weight) (FIG. 3) cannabidiol was administered in the form of a liquid formulation.

[0021] Under general anesthesia, four depth electrodes were implanted into the prefrontal cortex, the hippocampus, the striatum, and the reticular formation of the rats. From the head of the rats, signals are wirelessly transmitted by radio to a computer. At the same time, the physical activity is measured.

[0022] The signals are subjected to a frequency analysis, for example using the fast Fourier transform (FFT), and the frequency content of a signal is determined. In the case of EEG data, the spectrum is divided into multiple regions, which historically are denoted by delta, theta, alpha and beta.

[0023] After the division into seven frequency ranges ((1) to (7), see FIGS. 1-3), the changes in the electric output after administration of a liquid formulation according to the invention comprising cannabidiol can be quantified and, taking the signals of the four brain regions into consideration, a specific change pattern, referred to as the “electropharmacogram (supra)”, is obtained (Dimpfel W., Pharmacological classification of herbal extracts by means of comparison to spectral EEG signatures induced by synthetic drugs in the freely moving rat. Journal of Ethnopharmacology 2013, 149, 583-589).

[0024] An increase in the gamma spectral power (7) (see FIG. 1) can be established at a dosage of 1 mg/kg to 5 mg/kg within the striatum, to a lesser degree in the reticular formation and prefrontal cortex, and not at all in the hippocampus. This specific increase can be observed for at least 4 hours. Gamma spectral power correlates with increased activity (Dimpfel W (2015) Drug Discovery and Translational Medicine. Neurophysiological Techniques Provide a Holistic Approach to Saving Animals. BoD Verlag Norderstetten). In contrast, no specific increase in gamma spectral power is established for a dosage of 15 mg/kg CBD (FIG. 3).

[0025] As a result, high dosages of cannabidiol in a liquid formulation, and more particularly 5 or 15 mg/kg (body weight) according to FIGS. 2 and 3, have a sedating effect. The EEG pattern or electropharmacogram corresponds to that of certain antidepressants and analgesic drugs. This is confirmed by the significant decrease in the activity index. At the lowest dosage, and in particular less than 5 mg/kg (body weight), less than 2 mg/kg (body weight), and preferably 1 mg/kg (body weight), an activating and invigorating effect was observed.

[0026] A preferred embodiment of the invention thus relates to a liquid formulation comprising cannabidiol and water and at least one emulsifier, wherein a dosage of 1 mg/kg to 5 mg/kg (body weight) CBD is administered/applied to a human or an animal.

[0027] In a preferred embodiment, a liquid formation can thus comprise up to 500 mg/L CBD, 300 mg/L CBD, 100 mg/L CBD, preferably 40 mg/L CBD, 50 mg/L CBD, 60 mg/L CBD and in particular 20 mg/L CBD, 10 mg/L CBD. Furthermore, a range of 50 mg/L to 300 mg/L CBD, and in particular 50 mg/L to 100 mg/L CBD, in a formulation according to the invention is preferred. The administration of 60 mg/L CBD of a liquid formulation, for example, allows a dosage of 1 mg/kg (body weight) at a body weight of 60 kg.

[0028] Positive properties that a corresponding beverage yields include a performance-enhancing, invigorating, agreeable, pleasant, but not psychoactive effect for humans or animals. These effects can already develop starting at 10 mg/L CBD in a liquid formulation.

[0029] Further positive effects include increased concentration, increased cognitive ability, and increased memory function.

[0030] The invention thus relates to a product, and in particular a pharmaceutical product or a dietary supplement in a liquid formulation comprising cannabidiol and water and at least one emulsifier for use and application to increase concentration, to increase physical, athletic and cognitive performance, and to increase memory function, if necessary along with auxiliary substances and additives.

[0031] The invention thus relates to an energy drink, comprising a liquid formulation comprising cannabidiol and water and at least one emulsifier, along with auxiliary substances and additives.

[0032] Due to the unexpected positive properties, the present invention considers, as a further embodiment, the option that the formulation or the beverage is present as mineral water, lemonade, tonic water, a sports, mineral, fruit, fruit juice, milk, whey or soft drink or an alcoholic beverage, such as beer, or as a drinking water preparation. In the broadest sense, the present invention relates to a life style product, and in particular to a product for enhancing performance.

[0033] Moreover, the invention likewise relates to a flavoring agent comprising cannabidiol in a liquid formulation. Such a flavoring agent according to the invention can be used as a quinine substitute, for example. The invention thus relates to a flavoring agent, comprising a liquid formulation comprising cannabidiol and water and at least one emulsifier.

[0034] In a further embodiment, the liquid formulation or the beverage can be mixed with flavor components. These flavor components are preferably used to mask the bitter taste, and a person skilled in the art will be able to provide corresponding flavor components. Examples of flavor components are preferably, without being limited to, food flavoring agents, as described in Regulation (EC) No. 1334/2008. In particular, fruit flavorings are preferred, such as lemon, strawberry and the like.

[0035] The present invention likewise considers the use of the claimed liquid formulation as a physiological restorative agent, and in this connection in particular in the form of a foodstuff or food supplement (see, e.g., without being limited thereto, EC Directive 2002/46/EC of Jun. 10, 2002), optionally comprising auxiliary substances and additives, or a functional food for humans or animals.

[0036] Additional advantages and characteristics of the present invention will be apparent from the description of exemplary embodiments. The following examples and figures are provided to describe the invention, without limiting the invention to these examples.

EXAMPLES

[0037] 20% (w/w) CBD is dissolved in Polysorbate 80 (heat in ultrasonic bath for approximately 1 hour, if necessary in a water bath). Thereafter, 0.1 g of the clear CBD solution is added to 0.5 L Sprite® (=lemon-flavored soft drink) using a pipette. Should the CBD solution not be clear, this must continue to be dissolved in the ultrasonic bath or optionally heated in a water bath. Initially, minor turbidity of the drinking solution on the surface develops. The bottle is closed and placed for approximately 45 seconds into an ultrasonic bath, whereby the entire bottle becomes slightly turbid. Initially, a small amount of white foam settles on the neck of the bottle, which is to settle prior to consumption. The bottle is now shaken lightly and briefly and is ready for use.

[0038] FIG. 1, electropharmacogram (1.0 mg/kg CBD), relative change pattern over time:

[0039] Time-dependent progression of the electric output (“spectral power”) (ordinate) in percent from the 45-minute long pre-drug base line (values) in four brain regions of freely moving rats in the presence of a vehicle (4 ml/kg). The frequency ranges are depicted as bars on the abscissa, specifically delta (1), theta (2), alpha1 (3), alpha2 (4), beta1a (5), beta1b (6) and gamma spectral power (7) from left to right, depending on the named brain region, The statistical significance is represented in stars compared to the control group (vehicle): *=p<0.05; **=p<0.01.

[0040] FIG. 2, electropharmacogram (5.0 mg/kg CBD), otherwise as in FIG. 1.

[0041] FIG. 3, electropharmacogram (15.0 mg/kg CBD), otherwise as in FIG. 1.